With recent advances in computer and optics engineering, diagnostic endoscopy of the respiratory tract has now entered the era of microscopic imaging [1, 2] . Currently available microendoscopic devices use the principle of confocal fluorescence microscopy, where the microscope objective is replaced by optical fibres, which conduct both the excitation light to the tissue and the tissue fluorescence back from the fibre tip. Such systems analyse the spatial distribution of specific tissue fluorophores, or alternatively exogenous fluorophores, at the interface with the distal part of the optics. Over the last 5 yrs, fluorescence confocal microendoscopy has been successfully applied to the in vivo explorations of the gastric and colonic mucosae, the biliary tract [3] [4] [5] [6] and, more recently, to the microscopic imaging of the proximal and distal respiratory systems [7, 8] .
Translating confocal microscopy into the clinic for endomicroscopic explorations is the subject of significant scientific efforts [9, 10] , which recently ended in the availability of commercial systems for both animal [11] [12] [13] and human in vivo explorations [5, 7, 8, 14] . To take into account the problem of both the small size and relative inaccessibility of the human respiratory system, respiratory endomicroscopic systems use the principle of fibred confocal fluorescence microscopy (FCFM) or catheter-based confocal microscopy.
Principles of FCFM
Confocal microscopy allows in vivo optical sectioning of cells and tissue with enhanced lateral and axial resolutions [9, 10] , resulting in the imaging of a thin slice of a sample. The principle of confocal microscopy relies on both the use of a narrow point source on the illumination path and of a small aperture or pinhole on the light detection path. According to this principle, a laser source (the point source) focuses on a single spot in the sample and the light emitted from this focal point is imaged through the pinhole onto a detector. This results in the rejection of out-of-focus information from the material above and below a very thin plane of focus. The illumination and detection systems being conjugated on the same focal plane are termed ''confocal''. In order to obtain a two-dimensional image within the tissue, confocal microscopes must scan the sample in both lateral dimensions.
Respiratory confocal microendoscopes differ from the first confocal fluorescence endoscopes used for gastro-intestinal (GI) imaging by the technical approach used to scan the tissue. The Optiscan1/Pentax endomicroscope used for GI system exploration [15] uses a small scanhead (4.5 cm long, 3.5 mm diameter) that is included in the distal end of the endoscope. Optiscan1 endomicroscopic images from the GI tract appear very close to conventional histology, with a lateral resolution below 1 mm and optical slices of 7 mm for a field of view of 4756475 mm. Two drawbacks explain why this system is not yet available for respiratory tract imaging. First, because of the added sizes of the distal scanhead, working channel, conventional light guide and CCD camera, the diameter of the distal tip of the endoscope is currently larger than 12 mm, a size barely compatible with the exploration of the human trachea and large main bronchi. Secondly, the miniaturisation of the distal scanhead results in scanning rates of 1 frame?s -1 , which needs a very efficient stabilisation system of the distal tip of the endoscope onto the mucosae, in order to produce crisp microscopic images of the epithelium.
To date, the only commercially available confocal endomicroscope for respiratory explorations (Cellvizio1, Mauna Kea Technologies, Paris, France), which also allows GI explorations, uses the principle of proximal scanning, in which the illumination light scans the proximal part of a coherent fibre bundle or miniprobe. This bundle conducts the light back and forth from the imaged area at the tip of the miniprobe. The light delivery, scanning, spectral filtering and imaging systems are located at the proximal part of the device, the distal part being a separate miniprobe, including both the fibre bundle and its connector to the laser scanning unit ( fig. 1 ).
Photodetector
Laser source This fibre bundle based system, also described as FCFM, uses very thin and flexible miniprobes (300 mm-2 mm in diameter) that can contain up to 30,000 compacted microfibres. Similar to conventional confocal microscopes, FCFM uses two rapidly moving mirrors to scan the microfibres across the coherent fibre bundle in a raster fashion. Each microfibre, scanned one at a time by the laser light, acts as a light delivery and collection system and is, in essence, its own pinhole.
The main advantages of this design is the very small size of the probe that can reach the more distal part of the lungs, as well as the fast image collection speed that helps to avoid artefacts due to tissue movement.
Specific miniprobes for bronchial and alveolar imaging have a diameter of 1 mm, twice the size of an alveolar duct ( fig. 1 ). These miniprobes can enter the 2-mm working channel of adult bronchoscopes and reach any part of the lungs except the apical and posterior segments of both upper lobes, due to the relative stiffness of the probe's distal part ( fig. 2) [8] . Respiratory miniprobes are devoid of distal optics and have a depth of focus of 0-50 mm, a lateral resolution of 3 mm for a field of view of 6006600 mm. The system produces endomicroscopic imaging in real time at 9-12 frames?s -1 . Two different wavelengths are available ( fig. 2 ). The Cellvizio1 488 nm is used for autofluorescence imaging of the respiratory tract as well as for fluorescein-induced imaging of the GI tract [6] [7] [8] . Another device at 660 nm excitation can be used for epithelial cell imaging after topical application of exogenous fluorophores such as methylene blue [16] [17] [18] .
The main limitations of the system are related to its maximal imaging capabilities (30,000 pixels), which restrict the lateral resolution to the fibre intercore distance (3 mm), and the fact that the focus point of the system cannot be adjusted. Interpretation of the data also relies on the fluorescence properties of the imaged tissue.
Human in vivo confocal microimaging of the normal lung using FCFM Early ex vivo experiments using fresh adult human lung samples have demonstrated that, at 488 nm excitation wavelength, FCFM produces a thin fibre network imaging, corresponding to the connective tissue autofluorescence of the lungs ( fig. 3) . This made it possible to conduct in vivo microscopic explorations during bronchoscopy in humans, from the proximal bronchial tree down to the most distal acinar structures of the lung.
Nature of the autofluorescence bronchial and alveolar signals
Fluorescence properties of the bronchial mucosae at 488 nm excitation are determined by the concentration of various cellular and extracellular fluorophores, including the intracellular flavins, that could originate from the epithelial cells, and specific crosslinks of collagens and elastin present in the subepithelial areas [10, 19, 20] . Microspectrometer experiments coupled with FCFM imaging have clearly demonstrated that the main fluorescence signal emitted after 488 nm excitation from both the bronchial and alveolar human system originates from the elastin component of the tissue (fig. 4) [7, 8, 21] . In contrast, the collagen fluorescence does not seem to significantly affect the FCFM image produced at 488 nm, the fluorescence yield of collagen at this wavelength being at least one order of magnitude smaller than that of elastin. Along the same lines, flavin cellular autofluorescence appears too weak to allow imaging of the epithelial layer using 488 nm FCFM [22] .
FCFM devices using shorter wavelength may produce slightly different imaging of the bronchial wall connective tissue ( fig. 3 ). However, imaging the epithelial layer on top of the basement membrane network needs another approach, the accessible way being currently the use of an exogenous fluorescent dye [18, 23] . In the future, devices based on multiple wavelengths [24] , the adjunction of a reflectance device [10] or a multiphoton approach [9] may enable imaging of collagen, elastin and flavins simultaneously.
As a result, 488 nm excitation FCFM specifically images the elastin respiratory network that is contained in the basement membrane of the proximal airways and participates in the axial backbone of the peripheral interstitial respiratory system. In vivo autofluorescence microimaging of the proximal bronchial wall FCFM can easily be performed during a fibreoptic bronchoscopy under local anaesthesia [7, 8] . The technique of in vivo bronchial FCFM imaging is simple: the miniprobe is introduced into the 2-mm working channel of the bronchoscope and the probe tip applied onto the bronchial mucosae under sight control. The depth of focus being 50 mm below the contact surface, the system can image the first layers of the bronchial subepithelial connective tissue, presumably the lamina densa and the lamina reticularis [7] .
At 488 nm excitation, FCFM produces very precise microscopic fluorescent images of the bronchial basement membrane zone. As seen in figure 5, in vivo FCFM bronchial microimaging reveals a mat of large fibres mainly oriented along the longitudinal axis of the airways with crosslinked smaller fibres, as well as larger openings (100-200 mm) corresponding to the bronchial gland origins. In vivo, the technique also makes it possible to record high-resolution images of small airways such as terminal bronchioles, -Nature of the fibred confocal fluorescence microscopy signal (autofluorescence, 488 nm illumination) in proximal bronchi and alveoli, in both smokers and nonsmoking subjects, as deduced from in vivo spectrometry experiments. a) Typical normalised autofluorescence spectra of healthy bronchial mucosa (orange), elastin powder (pale blue) and collagen (purple) excited at 488 nm. b) Autofluorescence spectra of healthy bronchial mucosa (orange), carcinoma in situ (dark blue) and Mounier Kü hn syndrome (brown) at 488 nm excitation. Autofluorescence emission spectra of alveolar systems from c) nonsmokers (red) and d) healthy smokers (green, pink, yellow), during in vivo alveoscopy. c and d) Pale blue: elastin powder. d) Black: smoked cigarette. AU: arbitrary units. a and b) Reproduced from [7] , with permission from the publisher; c and d) reproduced from [8] .
which are recognisable by the presence of the helicoidal imprint of the smooth muscle on the inner part of the bronchiole ( fig. 5) [7] .
Application of the FCFM imaging system for the exploration of proximal bronchial diseases is still at its beginning, with early results being published on bronchial wall remodelling in benign [7] and preinvasive bronchial lesions [7, 18] .
In vivo assessment of bronchial wall remodelling FCFM imaging of the bronchial wall microstructure underlying premalignant epithelia is significantly modified [7] . In these precancerous conditions, the elastic fibred pattern of the lamina reticularis disappears in most cases, while appearing disorganised in about one-third of the lesions, supporting the hypothesis of an early degradation of the basement membrane components in preinvasive bronchial lesions ( fig. 6 ) [7] . Whether early remodelling of the lamina reticularis is associated with specific outcomes of the lesions should be further explored.
However, while this observation shed some light on the origin of the autofluorescence defect in precancerous bronchial lesions, the absence of epithelial cell visualisation in this study did not allow the technique to differentiate between the different grades of progression of the precancerous bronchial lesions such as metaplasia/dysplasia/ carcinoma in situ (see section on FCFM assessment of the bronchial epithelial cell layer, and figure 6 ). Besides the study of the premalignant bronchial wall alterations, the application of FCFM could be extended to the field of nonmalignant bronchial diseases. In one study, a complete disappearance of the bronchial wall fibred connective network was observed in a tracheomegaly syndrome, a pathological condition related to a defect in elastic component of the bronchial wall [7] . The same study also observed a remarkable FCFM aspect in a case of sarcoidosis, corresponding to subepithelial granuloma upon bronchial sampling. Whereas still limited, these observations indicate that per endoscopic FCFM could be used to study specific basement membrane remodelling alterations such as in chronic bronchial inflammations, asthma and chronic obstructive pulmonary disease. 
FCFM assessment of the bronchial epithelial cell layer
In order to be successfully applied to the exploration of precancerous/cancerous bronchial epithelium, the FCFM technique would need to be coupled with the use of an exogenous nontoxic fluorophore. Ex vivo studies have shown that the resolution of the system is not a limitation for nuclear or cellular imaging [7, 8] . Exogenous fluorophores that could be activated at 488 nm, such as acriflavin (a putative mutagen agent) or fluorescein solution, which does not stain the nuclei [25] , are not approved for intrabronchial use. Recently, LANE et al. [23] have used a confocal microendoscope prototype at 488 nm excitation and topical physiological pH cresyl violet to provide cellular contrast in the bronchial epithelium both in vitro and in vivo.
Methylene blue is a nontoxic agent which is commonly used during bronchoscopy for the diagnostic of bronchopleural fistulae. It is also used in gastroenterology for chromoendoscopic detection of precancerous lesions [26] [27] [28] , as well as for in vivo microscopic examination of the GI tract and bronchus using a novel endocytoscopic system [29, 30] . Methylene blue is a potent fluorophore that enters the nuclei and reversibly binds to the DNA, before being reabsorbed by the lymphatics. In order to give a fluorescent signal, methylene blue needs to be excited around 660 nm, and is therefore accessible to FCFM intravital imaging using this excitation wavelength.
Preliminary study has demonstrated that Cellvizio1 660/topical methylene blue makes it possible to reproducibly image the epithelial layer of the main bronchi ( fig. 6) [18] . Future studies using this technique could make it possible to differentiate normal, premalignant and malignant alterations at the microscopic level in vivo. If this strategy is successful, FCFM may become a very powerful technique for in vivo diagnosis of early malignant and premalignant conditions of the bronchial tree, allowing the analysis of both the epithelial and subepithelial layers during the same procedure.
Distal and transitional bronchial imaging
When progressing towards the more distal parts of the bronchial tree, small noncartilaginous bronchioles are easily recognisable because of the helicoidal imprint of the smooth muscles on the bronchiolar walls ( fig. 5) . However, the orthogonal branching and the small calibre of the terminal and respiratory bronchioles in humans compared with the probe size implies that the progression of the probe towards the acinus regularly bypasses the transitional respiratory bronchioles. While FCFM images of alveolar buds in respiratory bronchioles could be observed casually ( fig. 5 ) [8] , FCFM study of the distal membranous and respiratory bronchioles appears difficult, unless thinner probes, currently devoted to experimental animal imaging, become clinically available in the future [13] .
FCFM imaging of the acinus and peripheral connective tissue network
Earlier work has demonstrated that elastin represents up to 50% of the peripheral lung connective tissue fibres [31] . Following the first work on the proximal bronchi, FCFM rapidly appeared to be able to image the elastic framework of the distal lung as well [8] . In the acinus, elastin is present in the axial backbone of the alveolar ducts and alveolar entrances, as well as in the external sheath of the extra-alveolar microvessels [32, 33] , explaining the nature of the intra-acinar FCFM imaging (figs 3 and 7).
For distal lung microimaging, the use of a small bronchoscope with a 2-mm working channel appears useful in order to more efficiently orientate the probes into the regions of interest. The FCFM miniprobe is then gently advanced into the distal bronchiole until the alveolar system is observed. During the procedure, several acinar areas can be successively explored by selecting different bronchioles, with real-time imaging. Once the alveoli are reached, the probe is slightly pulled back until the contact is lost, to ensure that the probe compression effect onto the alveolar system is minimal.
Experience of in vivo FCFM alveolar imaging has demonstrated that the technique is very well tolerated under topical anaesthesia in spontaneously breathing awake subjects. Due to the lack of pain receptors in the bronchial tree down to the subpleural level, the penetration of the miniprobe into the pulmonary lobule through the distal bronchiolar wall is painless [8] . In addition, acinar imaging is not associated with significant bleeding in the proximal airways, in contrast to what is usually observed with transbronchial biopsy sampling. This is explained by the low pressure in the alveolar capillaries that could be altered during the progression of the probe, as well as by the smooth design of the probe tip that can displace the extra-alveolar microvessels without damage. No pleural complication occurred in our experience in more than 150 patients and healthy volunteers, despite multiple lung segment imaging during the endoscopy, when the system is used in awake, spontaneously breathing subjects.
Acinar FCFM imaging in nonsmoking subjects
Acinar imaging is easily obtained by pushing forward the probe a few centimetres after the endoscope is distally blocked into a subsegmental bronchus. Due to the respective sizes of the probe tip and of the distal bronchiolar structures, the entry into the alveolar space is obtained by penetration through the thin wall of a small distal bronchiole.
In nonsmokers, FCFM mainly produces images of the elastic fibres that encircle the alveolar openings, reinforce the virtual wall of the alveolar ducts and surround the extraalveolar microvessels (fig. 7) .
The in vivo aspects of this distal elastic framework may vary depending on the angle of penetration of the probe into the alveolar unit. A direct view down the axis of the duct or an oblique view could be commonly obtained, from which the ''helical'' or ''looped'' shape of the duct's elastic structure could be easily recognised ( fig. 7 ) [8] .
The reproducibility of the technique has been demonstrated in a series of healthy volunteers, where alveolar opening sizes measured from in vivo imaging were found normally distributed with mean values (around 275 mm) close to what is observed using complex stereological methods in vitro [32, 33] , with thickness of the elastic fibres being 10¡2.7 mm (table 1 and fig. 8 ) [8] . In the published series, smaller alveolar mouths were observed in the right upper lobe and paracardiac segments, presumably in relation to the lower ventilation of these segments in supine position [8] . The technique also enables precise measurements of the extra-alveolar lobular microvessels.
Interestingly, significant variation in the intensity of the autofluorescence signal could be observed between the subjects, the oldest individuals presenting the strongest signal, indicating structural modifications of lung elastin crosslinks in relation to ageing. Data are presented as n or mean¡ SD, with the exception of microvessel diameter, which is presented as median¡interquartile range. # : p,0.0001, Chi-squared test. Adapted from [8] .
Acinar and alveolar imaging in active smokers
Alveolar fluorescence imaging in active smokers dramatically differs from imaging in nonsmokers ( fig. 7) . The alveolar areas of smokers are usually filled with highly fluorescent cells corresponding to alveolar fluorescent macrophages, the presence of which appears very specific to active smoking. Using FCFM, morphological markers of alveolar macrophage activation such as size, number and mobility can be assessed, which appear highly correlated with the amount of cigarettes smoked per day ( fig. 8) [8] .
The alveolar autofluorescence intensity appears significantly higher in active smokers compared with nonsmokers, in relation to the intensity of the macrophage alveolitis. In situ alveolar microspectrometric measurements have been performed in active smokers, which showed that the main fluorophore contributing to the FCFM alveolar signal corresponds to the tobacco tar by itself, explaining this difference ( fig. 4) [8, 21] . Due to this specific contrast imaging in smokers, details of the alveolar and ductal surface could often be obtained ( fig. 7) . 
Potential applications and possible limitations of FCFM for distal lung imaging
The broncho-alveoscopy procedure is the first technique that makes it possible to obtain real-time, high-resolution, microstructural images of lobular and alveolar lung structures in living humans. As such, the technique appears to have a great potential for in vivo, minimally invasive exploration of the distal lung. For distal lung imaging, the technique could also be coupled with modern techniques of distal structure localisation and sampling, such as with electromagnetic navigation or miniprobe-based radial endobronchial ultrasound. FCFM clinical applications with the greatest potential are the assessment of diffuse peripheral lung diseases and in vivo diagnosis of peripheral lung nodules [17] .
Typical alterations of the elastic framework in a case of idiopathic pulmonary fibrosis and cellular imaging of a peripheral adenocarcinoma are shown in figure 9 . Whereas preliminary FCFM results in both these directions appear very encouraging, potential difficulties of the technique should be underlined. These difficulties are mainly related to the interpretation of the FCFM images and standardisation of the alveolar imaging.
Altered FCFM images of the acinar elastic network may be encountered in normal human lung, related to the compression and alterations of the fragile acinar framework during the progression of the probe. This is due to the mode of penetration of the probe into the acinus, which supposes the disruption of bronchiolar and alveolar walls, followed by a compression effect on the more resistant ductal structures. Minimal imaging distortion is observed when the probe is applied on the axis of the duct, resulting in the visualisation of more details in the background planes than theoretically allowed by the 50 mm depth of focus of the system [13] . This compression effect may be difficult to control in vivo. In our hands, the more reproducible results are obtained by gently pulling back the probe once the alveolar imaging is obtained and analysing the last images before the contact is lost. Therefore, future studies should include a standardisation of the endoscopic technique.
Conversely, FCFM exclusively records the signal coming from fluorescent structures in response to appropriate excitation wavelengths. In this regard, in its autofluorescence mode (i.e. without the use of exogenous fluorophore), in vivo FCFM in nonsmokers only images the elastin of the peripheral and axial connective tissues. Data from the literature indicate that such information might be helpful for the exploration of several peripheral lung diseases [34] [35] [36] . However, as the confocal fluorescence imaging of the distal lung is likely to appear very different from the corresponding histopathology, the semiology of the FCFM elastin lung network imaging will have to be characterised in pathological conditions. In this regard, in vivo comparative studies on confocal alveolar imaging in patients with peripheral lung diseases and healthy volunteers appear mandatory, before the place of FCFM in the routine exploration of the peripheral lung can be appreciated.
Until now, confocal microendoscopy of the airways has only used endogenous autofluorescence or simple fluorescent contrast agents to visualise the in vivo cellular and interstitial organisation of the airways and distal lung parenchyma. In the future, using molecular contrast compounds, it will be possible to extend the applications of the technique to the area of in vivo molecular imaging. Pilot studies exploring this strategy have recently been published that provided specific confocal imaging of molecular probes in precancerous conditions of the oral cavity ex vivo [37] and of colonic dysplasia in vivo [38] . Coupled to FCFM, molecular imaging may help in the future to enable early diagnosis, rapid typing of molecular markers and assessment of therapeutic outcome in many lung diseases.
Summary
In vivo endoscopic microscopy aims to provide the clinician with a tool to assess architecture and morphology of a living tissue in real time, with an optical resolution similar to standard histopathology. To date, available microendoscopic devices use the principle of fluorescence confocal microscopy, and thereby mainly analyse the spatial distribution of specific endogenous or exogenous fluorophores. Fluorescence microendoscopes devoted to respiratory system exploration use a bundle of optical fibres, introduced into the working channel of the bronchoscope. This miniprobe can be applied in vivo onto the bronchial inner surface or advanced into a distal bronchiole down to the acinus, to produce in situ, in vivo microscopic imaging of the respiratory tract in real time. Fluorescence confocal microendoscopy has the capability to image the epithelial and subepithelial layers of the proximal bronchial tree, as well as the more distal parts of the lungs, from the terminal bronchioles down to the alveolar ducts and sacs. Potential applications include in vivo microscopic assessment of early bronchial cancers, bronchial wall remodelling evaluation and diffuse peripheral lung disease exploration, as well as in vivo diagnosis of peripheral lung nodules. The technique has also the potential to be coupled with fluorescence molecular imaging. This chapter describes the capabilities and possible limitations of confocal microendoscopy for proximal and distal lung exploration.
